Healthcare Principal and Head of Business Development, Chief of Staff - Common and Rare Diseases

• 2020 - Present

Providing the strategic and tactical guide to the executive and leadership teams of biopharma companies and other healthcare ecosystem stakeholders (e.g. payers, patient/advocacy groups, hospitals, HCPs, governments, city authorities, policy makers) throughout the health value chain and patient journey so that enable evidence-based strategic planning and decision making - throughout the product lifecycle (drug/service), from early development through medical and commercialization, incl. pre-launch, launch, and life cycle management - from early symptoms and diagnosis, through first treatment to disease management and continuity of careThe best customer experience design and solutions development (patients, HCPs, caregivers, Health systems), health digitalization, change management, capabilities development (internal/external)Situational analyses: customers/stakeholders map, customer journey and experience map, segmentation/personas development, actionable insights, evidence generation, health systems perspective, opportunities map with priorities, advocacy plans, market research, competitive intelligence, countries specificitiesBusiness and project delivery, transformative strategic and tactical initiativesResource allocation/managementPipeline and portfolio focusDrive value for the business, challenge the status quo, supporting big pharma in transforming from the silos culture into the sharing culture, psychological safety and learning ecosystem Common and rare diseases

HTAi Patient and Citizen Involvement Group

• 2021 - Present

PCIG brings together patients, citizens, patient advocates, clinicians, researchers, economists, country HTA agencies, governments and industry with a keen interests in real patient and citizen involvement in the HTA process. Capabilities building, best practice development/sharing PCIG brings together patients, citizens, patient advocates, clinicians, researchers, economists, country HTA agencies, governments and industry with a keen interests in real patient and citizen involvement in the HTA process. Capabilities building, best practice development/sharing

Board Trustee, Patient Advocacy Champion - Cardio-Metabolic Diseases, Common and Rare Diseases

• 2020 - Present

Familial hypercholesterolaemia (common and rare form) and other inherited lipid disorders. The European Patient Network of multi-disciplinary stakeholders, including 29 national patient organizations in 27 countries, medical and scientific communities Strategy, governance, general managementStrategic initiatives, advocacy, health policy interventions, digital innovationsMember of EURORDIS New Born Screening Working GroupSCREEN4CARE project, that aims to tackle the lengthy diagnosis journey, the major hurdle for rare disease patients, via an innovative research approach based on two central pillars: genetic newborn screening and artificial intelligence (AI)-based tools

Patient Expert of New Born Screening Working Group

• 2020 - Present

SCREEN4CARE, http://screen4care.euInnovative research approach accelerating diagnosis of rare diseases patients through genetic newborn screening and artificial intelligence-based technologiesPatient advocacy, policy-making, politicians influence SCREEN4CARE, http://screen4care.euInnovative research approach accelerating diagnosis of rare diseases patients through genetic newborn screening and artificial intelligence-based technologiesPatient advocacy, policy-making, politicians influence

Head of Outreach & Healthcare Partnerships Development - Rare Diseases

• 2017 - Present

US- and Swiss-based organization with a global reach. Rare disease community building, working with all actors. Bridging between biopharma industry-science-HCPs-patient groups-patients-governments-media Providing innovative, cost-effective solutions (digital/non-digital) in the rare diseases space to support biopharma companies, CROs, and patient organizations in execution of their strategic initiatives in key business areas: development, commercial, medical and patient advocacy*Patients/HCPs engagement, Innovative Partnerships Development, New Innovative Business Development, Market Research, customer insights and experience, Public Health initiatives *Patient-centric planning, patients empowerment, disease awareness raising, therapy/medical education, stakeholders maps, opportunities maps*Targeted heat-maps, outreach campaigns, media partnerships, tailored messaging, social media, ...*Content development, press releases, e-newsletters, events presence- Go-to market lead and business champion. Representing organization in the external environment of the broad rare disease community, interacting with C-suite, board-level executives and leadership teams, creating partnerships on CheckOrphan’s products and service offerings- Member of the leadership team- Building the European team based of clinicians, scientists and business professionals

Director Portfolio Management - Immune-Oncology, Immunology-Inflammatory, Oncology, Ophthalmology

• 2017 - Present

Previous Merck Serono, acquired by Fresenius Kabi in 2017Oncology, immune-oncology, rheumatology, gastroenterology, dermatology, ophthalmologyShaping aligned holistic bio strategy - through internal and external lenses - with global responsibility for strategic projects enhancing our product portfolio and Biosimilar platform. It includes: portfolio strategy, development (R&D/BD&L), commercial and manufacturing strategies. Decision-making guide, fit-for-purpose framework, competitive insights (CI)- Developed 5/10/15-years strategic planning with defined R&D and BD priorities, storyline, strategic rationale for new initiatives. Drove (1) strategic initiatives, next wave of assets for the portfolio and supporting commercial innovation and differentiation; new ideas incubation, external environment research, internal gap analyses, market evolution, competition mapping, (2) elaboration of the strategic plan across all key functions, orchestrate processes and deliverablesClosely working with executive team, preparation/delivery sharp presentations to Executive Committee and Investment Committee, ensuring buy-in within Organization- Therapeutic Area strategy from the product candidate targets selection to LCM, incl. synergies with other Fresenius Kabi BUs portfolio/commercial footprint/distribution channels, new TAsCross-functional Global Portfolio Management of in-line products, pipeline, and pipeline targets, various scenarios, incl. R&D and BD options and business casesIntegrated portfolio evaluation, cross-portfolio insights, deep dive analyses, qualitative/quantitative, IP/technical/clinical development/commercial assessment with overall attractiveness assessment, risk-reward profile, strategic fit, product competitive differentiation. Prioritization and recommendations, provided with the implementation plan, incl. resources constraints (top-down/bottom-up). Risk management, contingency plan- Led external multi-countries MR/CI consultancy projects, E2E

Biopharma Advisor Business Development and Portfolio Decision Support

• 2015 - 2017

Growth strategies, strategic planning, cross-functional global strategic initiatives, including BD, portfolio development and management, commercialization, manufacturing, business improvements. Applying the external and internal lenses to deliver insight-based, actionable recommendations to C-suite and leadership teams to enable the well informed decision making, direction setting, strategy development and execution.Competitive intelligence (CI), Market insights (MI), Market research (MR), Business analytics (BA)Strategic decision support, fit-for purpose framework. Developed and emerging markets Advisory provided to:Pharma/Biotech/CDMO - corporate, growing organizations, start-upsConsulting firmsInvestorsCore therapeutic areas: immune-oncology, oncology, immunology, auto-immmune/inflammatory diseases, gastroenterology, rheumatology, dermatology, neuroscience, allergy, nephrology, respiratory, ophthalmology, haematology, infectious/multi-drug resistance, cardiovascular, women's healthLarge molecules, antibodies, proteins, small moleculesStrategic Planning/Direction/ExecutionBusiness Insights & Analytics, Strategic & Operational PlanningPipeline/Portfolio Strategy, Evaluation, Prioritization (R&D, BD&L)Complementary Portfolio/ Alternative Scenarios & OptionsCommercial Footprint/Roadmap/Roll-outCommercialization Strategies/Go-To-Market Models, International Markets, Markets PrioritizationBusiness Development/Licensing/Partnering Opportunities Search & AssessmentThe Best Opportunities Identification / Investments & PartnersStrategic Selection of 3rd party partners / Valuate, negotiate & close deals/ Cross-functional Due DiligenceM&As / Buy- & Sell-sideOrganizational Infrastructure & Capability / New AffiliatesInvestment Presentations & RecommendationsDelivery on TPPs, Brand Plans, Launch readiness

Director Business Development & Strategic Alliances, Commercial Operations

• 2014 - 2015

Start-up of all commercial operations out of the USInternational expansion of company commercial footprint from a scratchEnd-to-End Business Development, Commercial strategy, Strategic roadmap, Roll-out / International marketsStrategic Alliances, Collaborations, 3rd Party PartnershipsCross-functional Due Diligence & ManagementAgreements Negotiations & ClosureBusiness Analytics, Insights & ValuationsBest Market Entry Strategies, Go-to-Market Models, Infrastructure P&L, Business reviews/Sales meetingsM&As / Post-Merger Synergy & IntegrationsPortfolio Development & OptimizationPipeline Enhancement, Product SelectionBusiness Processes Implementation & Optimization

Director Business Development & Licensing

• 2011 - 2014

Business Development, Commercialization & 3rd Party Partnering StrategiesPortfolio & Pipeline Management / Strategic MarketingStrategic Development, Business PlanningQuality Decision-making SupportCommercial Insights, Business Analytics, Market Research, Competitive IntelligenceCommercial & Financial ValuationModelling, Forecasting, P&L, Business reviews, Sales meetingsDue Diligence, Business Case Development'Win-Win' Partnerships Building & Management incl. Search & Transactions / B2BAgreements Negotiations & Management / Alliance ManagementEnsured Compliance with Procedures, Regulations & LawsLong-Range Planning, Revenue & Profit Projection, BudgetingRisk Assessment & Mitigation, Key Variables Impacting Potential Return

Director Out Licensing

• 2008 - 2011

Decision-Analytics, Quality Decision-making SupportPortfolio Strategy Development & Management / New Initiatives / Commercial & R&DSet up 5/10-years Business Plan on annual basis with the defined Portfolio targets / various scenariosProject Assessment / Contribution / Review / PrioritizationCompetitive Assessment / Marketed products, in launch phase, pipeline & pipeline candidatesLicensing Strategy & ExecutionB2B PartnershipsNegotiate & Close Deals / Post-signature Alliance Management / Agreements Management Product Strategy / Strategic PlanningForecasting & BudgetingRisk Mitigation

Project Manager Business Development & Licensing

• 2003 - 2008

Business Development and Strategy for Central & Eastern Europe, Russia and CISProject Planning, Budgeting & ExecutionReview & PrioritizationState-of-the-art Project Management / Processes & Best Practices Implementations End to End Licensing / Screen, Seek, Assess, ExecuteCross Functional Due Diligence Leadership & Team Management Business Case & Rationale / Fact-based Recommendations, Alternative ScenariosAgreements Negotiations, Closure / Post-signature Alliance ManagementDigital Systems BuildingInterface & Data Architecture DesignTranslating Business Requirements into Technical RequirementsDevelopment, Implementation, Execution Single Point of Contact for Internal & External Stakeholders

Manager Market Insights, Competitive Intelligence - Knowledge Management

• 2003 - 2003

Provided market & strategic insights and analyses, monitored trends, benchmarking, competition mapping to support BD and R&D decisions

Researcher, novel antiviral and oncology drug candidates, Multi-Drug Resistance (MDR)

• 2002 - 2003

Researcher in Drug Discovery, novel drug candidates against HIV, Multi Drug Resistance (MDR)

• 2000 - 2002